Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo’s Next Chapter Will Be Led By CEO De Silva

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.

You may also be interested in...



Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix

Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.

Endo Bids For Salix; Valeant May Be Thwarted Again

Endo confirmed March 11 that it has offered to acquire the GI specialist for $175 per share, trumping Valeant’s $158 per share offer announced in February.

Auxilium Accepts Endo Offer, Dumps QLT Merger Plans

Endo seals the deal with Auxilium in a $2.6 billion acquisition that will add to its men’s health business and won’t prevent it from continuing on its M&A spree.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel